Lead sponsor
Sanofi
60 GLP-1 and incretin trials led. Source: ClinicalTrials.gov, as of July 6, 2026.
60
Trials led
2
Ongoing
31,515
Total enrollment
2,170
Sites
Distinct sites across this sponsor's lead trials. A site running several of them counts once, matching the map. Total enrollment sums each trial's reported enrollment, whether planned or actual.
Portfolio
How this sponsor's trials break down
Trials by phase
Phase 1
10
Phase 2
7
Phase 3
35
Phase 4
8
Trials by status
Recruiting
1
Active, not recruiting
1
Completed
51
Terminated
6
Withdrawn
1
Trials led
TrialEligibility highlightPhaseStatusEnrollment
Dose Ranging Study of the GLP-1 Agonist AVE0010 in Metformin-Treated Subjects With Type 2 Diabetes MellitusBMI 25-40Ph 2Completed542
Comparison of Lixisenatide Injected Prior to the Main Meal of the Day Versus Prior to Breakfast in Type 2 Diabetic Patients on Metformin-Ph 3Completed451
Assessment of the Efficacy and Safety of Lixisenatide in Patients With Type 2 Diabetes Insufficiently Controlled With Basal Insulin +/- Metformin-Ph 3Completed447
Safety And Tolerability Of Lixisenatide In Monotherapy In Patients With Type 2 Diabetes-Ph 3Completed361
Efficacy and Safety of Insulin Glargine/Lixisenatide Fixed Combination Versus Insulin Glargine Alone on Top of Metformin in Type 2 Diabetic Patients-Ph 2Completed323
24-week Study Comparing Lixisenatide to Sitagliptin as add-on to Metformin in Obese Type 2 Diabetic Patients Younger Than 50 YearsBMI ≤50Ph 3Completed319
A Study to Assess the Safety and Efficacy of SAR425899 in Patients With Type 2 Diabetes Mellitus-Ph 2Completed296
Safety and Tolerability of Lixisenatide in Combination With Oral Anti-Diabetic Treatment in Patients With Type 2 Diabetes-Ph 3Completed294
Efficacy and Safety of the Insulin Glargine/Lixisenatide Fixed Ratio Combination Versus Insulin Glargine in Patients With Type 2 Diabetes (LixiLan-India)BMI 19-40Ph 3Completed247
Effects of Lixisenatide Compared to Liraglutide on the Postprandial Plasma Glucose in Patients With Type 2 Diabetes-Ph 2Completed148
Pharmacodynamic Effects of Lixisenatide Compared to Liraglutide in Patients With Type 2 Diabetes Not Adequately Controlled With Insulin Glargine With or Without MetforminBMI 20-40Ph 2Completed142
Effect of Lixisenatide on Postprandial Plasma Glucose Compared to Sitagliptin in Combination With Insulin GlargineHbA1c 7-10%Ph 4Completed136
A Study to Investigate Safety and Efficacy of iGlarLixi in Adult Patients With Type 2 Diabetes MellitusBMI ≥25Ph 4Active, not recruiting105
Multiple Ascending Dose Study in Healthy Male Subjects and Overweight to Obese Male and Female Type 2 Diabetes Mellitus (T2DM) PatientsBMI 20-30Ph 1Completed76
First-in-human Study to Assess Safety and Tolerability of a Single Subcutaneous Dose of SAR441255 in Lean to Overweight SubjectsBMI 20-30Ph 1Completed48
A Clinical Study to Investigate the Effect of SAR425899 on Energy Expenditure in Obese SubjectsBMI 28-40Ph 1Completed24
Evaluation of the Blood Levels of the Drug (Lixisenatide), the Plasma Glucose Levels and Safety in Paediatric and Adult Patients With Type 2 DiabetesHbA1c 7-10%Ph 1Completed24
A Study on Safety, Pharmacokinetics and Pharmacodynamics of Lixisenatide in Pediatric Patients With Type 2 Diabetes Mellitus (T2DM)HbA1c 6.5-11%Ph 1Completed23
Relative Bioavailability and Activity of Different Formulations of Insulin Glargine and Lixisenatide in Patients With Diabetes Mellitus Type 1HbA1c ≤9%Ph 1Completed22
Postprandial Glucodynamic Response to Insulin Glargine/Lixisenatide Fixed Ratio Combination in Japanese Patients With Type 2 Diabetes MellitusBMI ≤35Ph 1Completed20
A Clinical Study to Investigate if SAR425899 Binds to the Liver and Pancreas in Overweight to Obese Type 2 Diabetes Mellitus PatientsBMI 28-38Ph 1Completed13
Effect of Lixisenatide on Postprandial Lipid Profile in Obese Type 2 Diabetic PatientsBMI ≥30Ph 2Terminated2